Agios Pharma (AGIO)
NASDAQ:AGIO
AGIO Stock Chart & Stats
$29.59
-$0.03(-0.09%)
At close: 4:00 PM EST
$29.59
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$22.24 - $46.00
Previous CloseN/A
Volume212.48K
Average Volume (3M)768.57K
Market Cap
$1.73B
Enterprise Value$1.68B
Total Cash (Recent Filing)$854.42M
Total Debt (Recent Filing)$40.21M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Apr 30, 2026EPS Estimate
-1.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding58,592,170
10 Day Avg. Volume660,477
30 Day Avg. Volume768,570
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue31.18
Enterprise Value/Gross Profit35.33
Enterprise Value/Ebitda-3.84
Forecast
1Y Price Target
$39.67Price Target Upside34.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-6.66
Revenue Forecast (FY)$91.25M
Bulls Say, Bears Say
Bulls Say
Commercial UptakeAnalyst notes that initial Aqvesme prescriptions and REMS certifications across academic centers and community hematologists indicate early physician engagement and access to the core thalassemia patient population, supporting a potential meaningful revenue ramp.
Pipeline CatalystsAnalyst highlights forthcoming clinical data readouts for tebapivat, AG‑236 and AG‑181 that could materially affect the company outlook and drive a re‑rating on positive results.
Regulatory PathwayAnalyst expects a favorable regulatory path for mitapivat in sickle cell disease following a planned pre‑sNDA meeting with the FDA, which could unlock substantial value if the agency signals a viable approval path.
Bears Say
Launch DynamicsAnalyst expects the Aqvesme launch to be gradual because REMS dynamics and typical payer hurdles are likely to limit early uptake.
REMS And Reimbursement DelaysAnalyst warns that REMS certification, required liver monitoring and payer prior authorization create a lag between prescription and revenue recognition, delaying near‑term sales realization.
Safety And Labeling OverhangAnalyst points out that the REMS program and a black box warning for hepatocellular injury represent a safety overhang that may restrain adoption and complicate the regulatory path in sickle cell disease.
Agios Pharma News
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $22.24 and its highest was $46.00 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $1.73B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Apr 30, 2026 which is in 34 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Feb 12, 2026. The company reported -$1.86 earnings per share for the quarter, beating the consensus estimate of -$1.954 by $0.094.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.81.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 58,592,170 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.86 in its last earnings report, beating expectations of -$1.954. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.67 (34.07% Upside)
$39.67 (34.07% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.25%
12-Months-Change
Fundamentals
Return on Equity
-31.07%
Trailing 12-Months
Asset Growth
-22.00%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and pipeline momentum: notable Q4 revenue growth (86% YoY), Afesmi U.S. approval and an encouraging early launch (44 prescriptions in five weeks), a robust near-term catalyst calendar, and a healthy balance sheet (~$1.2B). Offsetting risks include near-term revenue timing delays (10–12 week conversion from script to treatment), anticipated sequential U.S. revenue decline into early 2026 due to ordering and inventory dynamics, sizeable R&D/SG&A spend without a specific profitability timetable, and regulatory uncertainty around the sickle cell approval pathway. Overall, the positives (approval, growth, cash runway, and multiple upcoming data readouts) outweigh the operational and timing headwinds, supporting an optimistic outlook.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$39.67
▲(34.07% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
Currently, No data available
---